Advances in medical treatment of breast cancer in 2022

Cancer Innovation Pub Date : 2023-02-21 DOI:10.1002/cai2.46
Jingtong Zhai, Yun Wu, Fei Ma, Virginia Kaklamani, Binghe Xu
{"title":"Advances in medical treatment of breast cancer in 2022","authors":"Jingtong Zhai,&nbsp;Yun Wu,&nbsp;Fei Ma,&nbsp;Virginia Kaklamani,&nbsp;Binghe Xu","doi":"10.1002/cai2.46","DOIUrl":null,"url":null,"abstract":"<p>Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 1","pages":"1-17"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.46","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.46","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

Abstract Image

2022年癌症医学治疗进展
癌症已取代癌症成为全世界最常见的恶性肿瘤。癌症5年生存率达90%。癌症的系统治疗已发展成为一个成熟的系统,包括化疗、靶向治疗、内分泌治疗和免疫治疗。本文总结了2022年癌症化疗、靶向治疗、内分泌治疗和免疫治疗的年度进展,为未来的研究提供了有价值的信息,更好地指导癌症乳腺癌的个体化治疗,从而改善癌症乳腺癌患者的预后和生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信